natgillin/translations-raw huggingface dataset:
Vardenafil is rapidly absorbed after administration of vardenafil 10 mg orodispersible tablets without water.
Vardenafil se hitro absorbira po zaužitju orodisperzibilne tablete po 10 mg vardenafila brez vode.
vardenafil, or tadalafil
vardenafilom ali
Vardenafil:
Med vdihavanjem
Vardenafil:
salmeterol:
Vardenafil: AUC: ↑ 10-fold Cmax: ↑ 4-fold
Vardenafil: AUC: ↑ 10-krat Cmax: ↑ 4-krat
Varenicline
vareniklin
Varenicline (N=1130)
vareniklin
Varenicline (N=5072)
vareniklin
Varenicline binds with high affinity and selectivity at the α4β2 neuronal nicotinic acetylcholine receptors, where it acts as a partial agonist - a compound that has both agonist activity, with lower intrinsic efficacy than nicotine, and antagonist activities in the presence of nicotine.
Vareniklin se z veliko afiniteto in selektivnostjo veže na α4β2 nevronske nikotinske holinergične receptorje in na njih deluje kot delni agonist – spojina, ki ima tako agonistično delovanje (z manjšo intrinzično učinkovitostjo kot nikotin) kot antagonistično delovanje v prisotnosti nikotina.
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Vareniklin ni spremenil farmakokinetike bupropiona v stanju dinamičnega ravnovesja.
Varenicline is highly selective and binds more potently to the α4β2 receptor subtype (Ki=0.15 nM) than to other common nicotinic receptors (α3β4 Ki=84 nM, α7 Ki= 620 nM, α1βγδ Ki= 3,400 nM), or to non-nicotinic receptors and transporters (Ki > 1µM, except to 5-HT3 receptors: Ki=350 nM).
Vareniklin je močno selektiven in se na podvrsto receptorjev α4β2 veže močneje (Ki = 0.15 nM) kot na druge pogoste nikotinske receptorje (α3β4 Ki = 84 nM, α7 Ki = 620 nM, α1βγδ Ki = 3,400 nM) ali na nenikotinske receptorje in transporterje (Ki > 1 μM, razen na receptorje 5-HT3: Ki = 350 nM).
Varenicline is not recommended during pregnancy.
Uporaba vareniklina med nosečnostjo ni priporočljiva.
Varenicline safety and tolerability was assessed in a double-blind study of 128 smokers with stable schizophrenia or schizoaffective disorder, on antipsychotic medication, randomised 2:1 to varenicline (1 mg twice daily) or placebo for 12 weeks with 12-week non-drug follow-up.
Varnost in prenašanje vareniklina so ocenili v dvojno slepi študiji pri 128 kadilcih s stabilno shizofrenijo ali shizoafektivno motnjo, ki so jemali antipsihotike; v razmerju 2:1 so bili randomizirani v skupino, ki je prejemala vareniklin (1 mg dvakrat na dan), ali v skupino, ki je prejemala placebo; študija je trajala 12 tednov, obdobje spremljanja brez zdravila pa 12 tednov.
Varenicline undergoes minimal metabolism with 92% excreted unchanged in the urine and less than 10% excreted as metabolites.
Vareniklin se minimalno presnavlja; 92 % se ga nespremenjenega izloči v urinu in manj kot 10 % se ga izloči v obliki presnovkov.
Varenicline vs Bupropion
188/1.001 (18,8 %)
Varenicline vs NRT
133/1.025 (13,0 %)
Vargatef 100 mg capsules Nintedanib
Vargatef 100 mg kapsule nintedanib
Vargatef 100 mg soft capsules are peach-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “100”.
Mehke kapsule Vargatef po 100 mg so neprozorne podolgovate kapsule v barvi breskve, ki imajo na eni strani v črni barvi natisnjeno oznako podjetja Boehringer Ingelheim in številko 100.
Vargatef 100 mg soft capsules nintedanib
Vargatef 100 mg mehke kapsule nintedanib
Vargatef 100 mg soft capsules Vargatef 150 mg soft capsules
Vargatef 100 mg mehke kapsule Vargatef 150 mg mehke kapsule
Vargatef 150 mg capsules are brown-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “150”.
Zdravilo Vargatef, 150 mg mehke kapsule, so rjave barve, neprozorne in podolgovate, ki imajo na eni strani v črni barvi vtisnjeno oznako podjetja Boehringer Ingelheim in številko 150.
Vargatef 150 mg capsules Nintedanib
Vargatef 150 mg kapsule nintedanib
Vargatef 150 mg soft capsules nintedanib
Vargatef 150 mg mehke kapsule nintedanib
Vargatef capsules must be taken orally, preferably with food, swallowed whole with water, and must not be chewed or crushed.
Kapsule zdravila Vargatef je treba zaužiti cele z vodo, najbolje s hrano; ne sme se jih žvečiti ali drobiti.
Vargatef contains soya
Zdravilo Vargatef vsebuje sojo
Vargatef has minor influence on the ability to drive and use machines.
Zdravilo Vargatef ima manjši vpliv na sposobnost vožnje in upravljanja s strojii.
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Zdravilo Vargatef je indicirano v kombinaciji z docetakselom za zdravljenje odraslih bolnikov z lokalno napredovalim, metastatskim ali lokalno ponovljivim nedrobnoceličnim pljučnim rakom (non-small cell lung cancer – NSCLC) s histologijo adenokarcinoma po kemoterapiji prve izbire.
Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV %) ranging from 30 % to 40 %, apart from on the day of surgery and the following day when variability in exposure is high (70 %).
Variabilnost farmakokinetike rivaroksabana je zmerna; interindividualna variabilnost (koeficient variacije %) je od 30 do 40 %, razen na dan kirurškega posega in naslednji dan, ko je variabilnost izpostavljenosti visoka (70 %).
Variable Type of estimate; treatment
Spremenljivka vrsta ocene;
Variable/ statistic Cetuximab plus FOLFIRI
in FOLFIRI in FOLFIRI
Variations in blood pressure
spremembe krvnega tlaka
Variations of colour within this range do not affect potency.
Barvna odstopanja znotraj tega območja ne vplivajo na učinkovitost zdravila.
Variations of colour within this range do not affect potency.
Barvni odtenki v tem območju ne vplivajo na učinkovitost.
Varicella (titre
N = 527
Varicella virus Oka/Merck strain ................................................. ≥ 3.99 log10 PFU
Virus varicella-zoster, sev Oka/Merck ....................................................... ≥ 3,99 log10 PFU
Varicella virus Oka/Merck strain ................................................. ≥ 3.99 log10 PFU
Virus varicella-zoster, sev Oka/Merck ...................................≥ 3,99 log10 PFU
Varicella virus Oka/Merck strain ................................................. ≥ 3.99 log10 PFU
Virus varicella-zoster, sev Oka/Merck........................................................ ≥ 3,99 log10 PFU
Varicella virus Oka/Merck strain ................................................. ≥ 3.99 log10 PFU
Virus varicella-zoster, sev Oka/Merck..........................................................≥3,99 log10 PFU
Varicella virus Oka/Merck strain ................................................. ≥ 3.99 log10 PFU
Virus varicella-zoster, sev Oka/Merck........................................................≥3,99 log10 PFU
Varicella virus3 Oka/Merck strain (live, attenuated) ................... not less than 3.99 log10 PFU**
Virus noric3, sev Oka/Merck (živ, oslabljen) ...................................... najmanj 3,99 log10 PFU
Varicella virus3 Oka/Merck strain (live, attenuated) ................... not less than 3.99 log10 PFU**
Virus noric3, sev Oka/Merck (živ, oslabljen) ......................................najmanj 3,99 log10 PFU
Varicella virus3 Oka/Merck strain (live, attenuated) ................... not less than 3.99 log10 PFU**
Virus varicella-zoster3, sev Oka/Merck (živ, oslabljen).......................najmanj 3,99 log10 PFU
Varicella virus3 Oka/Merck strain (live, attenuated) not less than 3.99 log10 PFU**
Virus varicella-zoster3, sev Oka/Merck (živ, oslabljen) najmanj 3,99 log10 PFU
Varicella zoster virus antibody testing/vaccination
Določanje protiteles in cepljenje proti virusu varicella zoster
Varicella, Herpes zoster (vaccine strain)
norice, herpes zoster (cepilni sev)
varicella-zoster virus
virusa varicella
Varicella-zoster virus Oka/Merck strain, (live, attenuated) ≥19400 PFU
Virus varicella-zoster, sev Oka/Merck, (živi, oslabljen)  19.400 PFU
Varicella-zoster virus, Oka/Merck strain, (live, attenuated) ≥19400 PFU
Virus varicella-zoster, sev Oka/Merck, (živi, oslabljen)  19.400 PFU
Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19400 PFU (plaque-forming units).
Virus varicella-zoster1, sev Oka/Merck, (živ, oslabljen), ne manj kot 19.400 enot, ki tvorijo plak (PFU – plaque forming units).
Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19400 PFU (plaque-forming units).
Virus varicella-zoster1, sev Oka/Merck, (živ, oslabljen), ne manj kot 19.400 enot, ki tvorijo plak (PFU – plaque-forming units).
Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19400 PFU2 1produced in human diploid (MRC-5) cells
Virus varicella-zoster1, sev Oka/Merck, (živ, atenuiran) ne manj kot 19.400 PFU2 1pridobljen na humanih diploidnih (MRC-5) celicah
varicose veins in the gullet (oesophageal varices)
varikozne vene v predelu požiralnika,
Various doses of Volibris (2.5, 5 and 10 mg) have been compared with placebo (a dummy treatment) in two main studies involving a total of 394 patients with PAH, most of whom had class II or III disease that was of unknown cause or caused by connective tissue disease.
Različne odmerke zdravila Volibris (2,5 mg, 5 mg in 10 mg) so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, v kateri je bilo vključenih skupaj 394 bolnikov s pljučno arterijsko hipertenzijo, od katerih jih je večina imela bolezen funkcijskega razreda II ali III, ki ni imela znanega vzroka oziroma je bila povezana z boleznijo vezivnega tkiva.
Various malignancies have also been reported with use of Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).
Pri uporabi zdravila Enbrel so poročali tudi o pojavu različnih novotvorb, vključno z rakom dojke, pljuč, kože in bezgavk (limfom).
Various malignancies have also been reported with use of etanercept, including cancers of the breast, lung, skin and lymph glands (lymphoma).
Pri uporabi etanercepta so poročali tudi o pojavu različnih novotvorb, vključno z rakom dojke, pljuč, kože in bezgavk (limfom).
various steroids - such as dexamethasone, ethinyl estradiol, fluticasone
različni steroidi - kot so deksametazon, etinil estradiol, flutikazon,
Various visceral effects (discoloration, red foci at different organs, small colourless mass above atrio- ventricular valve, small gall bladder, malformed diaphragm) were also observed in single foetuses.
Pri posameznih plodovih so opazili tudi različne visceralne učinke (spremenjeno barvo, rdeča žarišča v različnih organih, majhno brezbarvno gmoto nad atrioventrikularno zaklopko, majhen žolčnik, malformirano diafragmo).
Varvara 123 51 Athens, Greece
123 51 Athens, Grčija
Varvara 123 51 Athens, Greece
Varvara 123 51 Athens, Grčija
Varvara Athens
Varvara Atene
Varvara, Athens, Greece
Varvara, Atene, Grčija
VAS: Visual Analogue Scale
VAS (Visual Analogue Scale): vizualna analogna skala
Vascular
(redki),
Vascular
Žilne bolezni
Vascular (extracardiac) disorders: Flushing.
Žilne bolezni: rdečica.
Vascular access thrombosis
tromboza žilnega pristopa
Vascular adverse reactions
Neželeni učinki, povezani z žiljem
Vascular and thrombotic events (blood clotting) in blood vessels such as disturbance of blood perfusion in the brain, retinal thrombosis, disturbed blood perfusion of the heart, heart attack, arterial thrombosis, dilatation of the wall of a blood vessel (aneurysm).
Žilni in trombotični dogodki (krvni strdki) v ožilju kot so motnje krvnega pretoka v možganih, tromboza mrežnice, motnje krvnega pretoka v srcu, srčni napad, arterijska tromboza, razširitev stene krvne žile (anevrizma).
vascular arterial occlusion,
zapora arterijskega žilja,
Vascular complications
Zapleti žilnega sistema
Vascular Death
Žilna smrt
Vascular disorder
zilna bolezen
Vascular disorder
Žilna bolezen
Vascular disorder
Žilne bolezni
Vascular disorder
žilna bolezen
Vascular disorders
aze v krvi
Vascular Disorders
Bolezni kože in podkožja
Vascular disorders
Bolezni mišično-skeletnega sistema in vezivnega tkiva
Vascular disorders
Bolezni prebavil
Vascular disorders
Bolezni sečil
Vascular Disorders
Bolezni živčevja
Vascular disorders
kožni),
Vascular Disorders
motnje
Vascular disorders
Motnje ožilja
Vascular Disorders
Motnje spanja Bruksizem
Vascular disorders
Organski sistem Neželeni učinki Žilne bolezni
Vascular disorders
Očesne bolezni
Vascular disorders
popuščanje,
Vascular disorders
Preiskave
Vascular disorders
Raynaudov fenomen
Vascular disorders
Splošne težave in spremembe na mestu aplikacije
Vascular disorders
Srčne bolezni
Vascular disorders
vročinski oblivi
Vascular disorders
Ţilne bolezni
Vascular disorders
Žilne bolezni s
Vascular disorders
Žilne bolezni:
Vascular disorders
žilne bolezni
Vascular disorders Common Uncommon
Zelo pogosti
Vascular disorders Common Uncommon
Žilne bolezni Pogosti občasni
Vascular disorders Not known: postural hypotension
Žilne bolezni Neznana pogostnost: ortostatska hipotenzija
Vascular disorders Rare: hypotension
Žilne bolezni Redki: hipotenzija
Vascular disorders Uncommon Hot flush
Žilne bolezni občasni navali vročine
Vascular disorders Uncommon: flushing
Žilne bolezni Občasni: zardevanje
Vascular disorders Vasculitis
Žilne bolezni Vaskulitis.
Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high dose chemotherapy followed by transplantation.
Pri bolnikih, zdravljenih z visokimi odmerki kemoterapije, ki ji je sledila presaditev, so občasno poročali o žilnih boleznih, vključno z vensko-okluzivno boleznijo in motnjami volumna tekočine.
Vascular disorders4
Žilne bolezni4
Vascular disorders:
Žilne bolezni
Vascular disorders: Not known: postural hypotension
Žilne bolezni: Neznana: ortostatska hipotenzija
Vascular disorders: Uncommon: flushing
Žilne bolezni: Občasni: zardevanje
Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced angiogenesis.
Receptor rastnega faktorja za žilni endotelij (VEGF – Vascular Endothelial Growth Factor) 2 je ključni posrednik pri angiogenezi, ki jo povzroča VEGF.
Vascular mortality
Žilna umrljivost
Vascular occlusion adverse events were more frequent with increasing age and in patients with prior history of ischaemia, hypertension, diabetes, or hyperlipidaemia.
Neželeni dogodki žilne okluzije so bili pogostejši pri starejših bolnikih in pri bolnikih z ishemijo, hipertenzijo, sladkorno boleznijo ali hiperlipidemijo v anamnezi.
vascular occlusion, aortic stenosis, thrombophlebitis, aortic aneurysm
zapora žilja, aortna stenoza, tromboflebitis, aortna anevrizma
Vascular pseudoaneurysmC
vaskularna psevdoanevrizmaC
vascular retinopathy bronchiectasis or history of pulmonary bleeding
okvare žil na mrežnici, bronhiektazije ali v anamnezi krvavitev v pljučih.
Vascular stents
Žilne opornice
vasculitides, lupus erythematosus, drug hypersensitivity (including anaphylactic shock), allergic disorders, auto-antibody positive
vaskulitis, eritematozni lupus, preobčutljivost za zdravilo (vključno z anafilaktičnim šokom), alergijske reakcije, pozitivna avtoprotitelesa
vasculitis (inflammation of blood vessels which can cause skin rashes, joint pain and kidney problems) neurological disorders such as encephalomyelitis (inflammation of the central nervous system), neuritis (inflammation of nerves) and a type of paralysis known as Guillain-Barré Syndrome
vaskulitis (vnetje krvnih žil, ki lahko povzroči kožni izpuščaj, sklepne bolečine in težave z ledvicami), nevrološke motnje, kot je encefalomielitis (vnetje osrednjega živčevja), nevritis (vnetje živcev) in ena vrsta paralize, ki ji pravimo Guillain-Barréjev sindrom.
vasculitis (inflammation of blood vessels which can cause skin rashes, joint pain and kidney problems) neurological disorders such as encephalomyelitis (inflammation of the central nervous system), neuritis (inflammation of nerves) and a type of paralysis known as Guillain-Barré Syndrome
vaskulitis (vnetje žil, ki lahko povzroči kožne izpuščaje, bolečine v sklepih in ledvične težave), nevrološke motnje, kot so encefalomielitis (vnetje osrednjega živčnega sistema), nevritis (vnetje živcev) in vrsta paralize, ki ji pravimo Guillain-Barréjev sindrom.
vasculitis (inflammation of blood vessels)
vaskulitis (vnetje krvnih žil)
vasculitis (inflammation of blood vessels);
vaskulitis (vnetje krvnih žil);
Vasculitis (inflammation of the blood vessels which can cause skin rashes, joint pain and kidney problems)
Vaskulitis (vnetje žil, ki lahko povzroči izpuščaje na koži, bolečine v sklepih in težave z ledvicami).
Vasculitis associated in very rare cases with transient renal involvement
Vaskulitis, v zelo redkih primerih povezan s prehodno prizadetostjo ledvic
Vasculitis necrotising and toxic epidermal necrolysis
nekrotizirajoči vaskulitis in toksična epidermalna nekroliza
Vasculitis with transient renal involvement
vaskulitis s prehodno prizadetostjo ledvic
vasculitis,
pnevmonitis,
Vasculitis: narrow SMQ “Vasculitis”
Vaskulitis: zoženo SMQ „Vaskulitis“
Vasculitisam
vaskulitisam
Vaso-occlusive crises in patients with sickle cell anaemia
Vazookluzivne krize pri bolnikih z anemijo srpastih celic
Vasodilatation
Neželeni učinek
Vasodilatation
vazodilatacija
Vasodilatation Flushing
vazodilatacija pordevanje
Vasodilating agents
lopinavir:
Vasodilating agents
Vazodilatacijska zdravila
Vasodilators (peripheral)
Vazodilatatorji (periferni)
vasodilators (used to widen blood vessels resulting from smooth muscle relaxation), or, if you are undergoing radiation therapy,
vazodilatatorje (zdravila, ki širijo krvne žile, tako da sproščajo napetost gladkih mišic), ali če se zdravite z obsevanjem.
Vasodilatory action
Vazodilatacijski učinki
Vasopressin regulates the level of water and sodium in the body.
Vazopresin uravnava ravni vode in natrija v telesu.
Vasopression is a hormone that helps prevent the loss of water from the body by reducing urine output.
Vazopresin je hormon, ki pomaga preprečiti izgubo vode iz telesa tako, da zmanjša izločanje urina.
Vasovagal reaction
vazovagalna reakcija
Vasovagal reactions1.
vazovagalne reakcije1
vasovagal, loss
inkopo, izgubo
Vaxelis can be given at the same time as other vaccines such as pneumococcal vaccines, measles- mumps-rubella-varicella (MMRV) vaccines, rotavirus vaccines or meningococcal C vaccines.
Cepivo Vaxelis se lahko daje istočasno z drugimi cepivi, kot so cepiva proti pnevmokokom, cepiva proti ošpicam, mumpsu, rdečkam in noricam (MMRV), cepiva proti rotavirusom ali cepiva proti meningokokom skupine C.
Vaxelis is a vaccine, which helps to protect your child against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and serious diseases caused by Haemophilus influenzae type b.
Vaxelis je cepivo, ki pomaga ščititi vašega otroka pred davico, tetanusom, oslovskim kašljem, hepatitisom B, otroško paralizo in hudimi boleznimi, ki jih povzroča Haemophilus influenzae tipa b.
Vaxelis is given to children from the age of six weeks.
Vaxelis dajemo otrokom, starim od šest tednov naprej.
Vaxelis suspension for injection in pre-filled syringe
Vaxelis suspenzija za injiciranje v napolnjeni injekcijski brizgi
Vaxelis will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or Haemophilus influenzae type b.
Cepivo Vaxelis preprečuje le bolezni, ki jih povzročajo patogeni Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, virus hepatitisa B, poliovirus ali Haemophilus influenzae tipa b.
Vaxelis will only help to prevent these diseases caused by the bacteria and viruses targeted by the vaccine.
Cepivo Vaxelis ščiti samo pred temi boleznimi, ki jih povzročajo bakterije in virusi, proti katerim je cepivo usmerjeno.
Vaxxitek HVT+IBD is a recombinant vaccine intended for use against Infectious Bursal Disease (also known as Gumboro Disease) and Marek’s Disease in chickens.
Zdravilo Vaxxitek HVT+IBD je rekombinantno cepivo, ki je namenjeno za uporabo proti bolezni Gumboro in Marekovi bolezni pri piščancih.
Vaxxitek HVT+IBD Suspension and solvent for suspension for injection
Vaxxitek HVT + IBD suspenzija in vehikel za suspenzijo za injiciranje
Vaxxitek HVT+IBD suspension and solvent for suspension for injection
Vaxxitek HVT+IBD suspenzija in vehikel za suspenzijo za injiciranje
Vc n=202a
TTP
Vc=VELCADE; Dx=dexamethasone; T=thalidomide a Thalidomide dose is increased to 100 mg from week 3 of Cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 onwards if 100 mg is tolerated. b Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles
Vc = VELCADE; Dx = deksametazon; T = talidomid a V 3. tednu 1. kroga se lahko odmerek talidomida poveča na 100 mg samo, če bolnik dobro prenaša odmerek 50 mg in na 200 mg v 2. krogu, če bolnik dobro prenaša odmerek 100 mg. b Bolniki, ki dosežejo vsaj delni odgovor po 4 krogih, lahko prejmejo do 6 krogov zdravljenja.
VCR (1.5 mg/m2/day, IV): days 1, 29
VCR (1,5 mg/m2/dan, i.v.): 1. in 29. dan
VCR (1.5 mg/m2/day, IV): days 1, 8 and 15
VCR (1,5 mg/m2/dan, i.v.): 1., 8. in 15. dan
VCR (1.5 mg/m2/day, IV): days 1, 8, and 15
VCR (1,5 mg/m2/dan, i.v.): 1., 8. in 15. dan
VCR (1.5 mg/m2/day, IV): days 1, 8, and 15
VCR (1,5 mg/m2/dan, i.v.):1., 8. in 15. dan
VCR 2 mg i.v. monthly for 13 months; Prednisolone 200 mg oral, 5 days per month for 13 months
VCR 2 mg i.v. mesečno v obdobju 13 mesecev; prednizolon 200 mg peroralno, 5 dni na mesec v obdobju 13 mesecev
VCR 2 mg i.v., days 6, 13, 20;
VCR 2 mg i.v., 6., 13., 20. dan;
VCR 2 mg total dose i.v., days 1, 8, 15, 22;
VCR skupni odmerek 2 mg i.v., 1., 8., 15., 22. dan;
VcR-CAP=VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
VcR-CAP = VELCADE, rituksimab, ciklofosfamid, doksorubicin in prednizon; R-CHOP = rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon; PN = periferna nevropatija
VDDx=vincristine, doxorubicin, dexamethasone; BzDx= bortezomib, dexamethasone; TDx=thalidomide, dexamethasone; BzTDx= bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy
VDDx=vinkristin, doksorubicin, deksametazon; BzDx=bortezomib, deksametazon; TDx=talidomid, deksametazon; BzTDx=bortezomib, talidomid, deksametazon; PN=periferna nevropatija
VDDx=vincristine, doxorubicin, dexamethasone; BzmbDx=bortezomib, dexamethasone; TDx=thalidomide, dexamethasone; BzmbTDx=bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy
VDDx=vinkristin, doksorubicin, deksametazon; BzmbDx=bortezomib, deksametazon; TDx=talidomid, deksametazon; BzmbTDx=bortezomib, talidomid, deksametazon; PN=periferna nevropatija
VDDx=vincristine, doxorubicin, dexamethasone; VcDx=VELCADE, dexamethasone; TDx=thalidomide, dexamethasone; VcTDx=VELCADE, thalidomide, dexamethasone; PN=peripheral neuropathy
VDDx = vinkristin, doksorubicin, deksametazon; VcDx = VELCADE, deksametazon; TDx = talidomid, deksametazon; VcTDx = VELCADE, talidomid, deksametazon; PN = periferna nevropatija
VE (95% CI)
IZ interval zaupanja
VE (95% CI)
UC (95 % IZ)
VE2
UC2
Vectibix 20 mg/mL concentrate for solution for infusion panitumumab
Vectibix 20 mg/ml koncentrat za raztopino za infundiranje panitumumab
Vectibix 20 mg/mL concentrate for solution for infusion.
Vectibix 20 mg/ml koncentrat za raztopino za infundiranje.
Vectibix contains the active substance panitumumab, which belongs to a group of medicines called monoclonal antibodies.
Zdravilo Vectibix kot zdravilno učinkovino vsebuje panitumumab, ki spada v skupino zdravil, imenovanih monoklonska protitelesa.
Vectibix has been shown to be effective at treating patients with metastatic cancer of the colon or rectum when used together with other cancer medicines and on its own:
Zdravilo Vectibix se je izkazalo za učinkovito za zdravljenje bolnikov z metastatskim rakom debelega črevesa ali danke, če je uporabljeno skupaj z drugimi zdravili za zdravljenje raka in samostojno.
Vectibix has been studied in five main studies in patients with metastatic cancer of the colon or rectum:
Zdravilo Vectibix je bilo raziskano v petih glavnih študijah pri bolnikih z metastatskim rakom kolona ali danke: